Early Detection Research Network

ADAM12

Aliases:
This biomarker is also known as:
  • ADAM metallopeptidase domain 12,
  • a disintegrin and metalloproteinase domain 12 (meltrin alpha),
  • ADAM12,
  • MLTNA,
  • ADAM 12,
  • MCMPMltna,
  • EC 3.4.24.-,
  • meltrin-alpha,
  • MLTN,
  • MCMP,
  • disintegrin and metalloproteinase domain-containing protein 12,
  • O43184,
  • Meltrin-alpha,

Description…

ADAM12 is a member of the ADAM (a disintegrin and metalloprotease) protein family. ADAM family members are membrane-anchored proteins structurally related to snake venom disintegrins, and have been implicated in a variety of biological processes involving cell-cell and cell-matrix interactions. ADAM12 has two alternatively spliced transcripts: a shorter secreted form and a longer membrane-bound form. The shorter form is found to stimulate myogenesis.

Datasets

There are no datasets associated with this biomarker.

Attributes
QA State: Curated
Type: Protein
HGNC Name: ADAM12

The following organs have data associated with this biomarker…

Attributes

Phase: Two
QA State: Under Review

Overview

ADAM12 is a transmembrane tumor vascular marker (TVM) that is selectively expressed in tumor vasculature and represents a promising target for vascular imaging or anti-vascular therapy of epithelial ovarian cancer.

Performance Comment

ADAM12 is very highly expressed in some epithelial ovarian cancer samples compared with normal ovaries but a significant number of cancer samples exhibited low levels of ADAM12. Thus, ADAM12 may hold predictive value, and it could be used for therapy, especially the long isoform, for patients whose tumors express it.

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

No associated publications found.